Vamil Divan
Stock Analyst at Guggenheim
(4.52)
# 169
Out of 4,814 analysts
230
Total ratings
61.29%
Success rate
13.55%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Reiterates: Buy | $214 | $173.00 | +23.70% | 24 | Apr 17, 2025 | |
| MRK Merck & Co. | Reiterates: Buy | $115 | $77.98 | +47.47% | 14 | Apr 17, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Buy | $47 | $14.92 | +215.01% | 8 | Apr 14, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $86 | $69.30 | +24.10% | 10 | Apr 11, 2025 | |
| JNJ Johnson & Johnson | Reiterates: Neutral | n/a | $157.44 | - | 15 | Apr 2, 2025 | |
| ASMB Assembly Biosciences | Initiates: Buy | $31 | $9.70 | +219.59% | 1 | Mar 25, 2025 | |
| ABSI Absci | Reiterates: Buy | $10 | $3.10 | +222.58% | 3 | Mar 20, 2025 | |
| PFE Pfizer | Reiterates: Buy | n/a | $22.15 | - | 22 | Mar 18, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $59 → $61 | $21.19 | +187.87% | 5 | Feb 27, 2025 | |
| INSM Insmed | Reiterates: Buy | $101 | $72.47 | +39.37% | 6 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $14.06 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.71 | +744.95% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.77 | - | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $20 | $7.44 | +169.00% | 9 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $0.29 | +8,978.21% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $0.90 | +904.69% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.84 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $14.71 | +29.16% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $100.10 | -2.10% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $27.05 | +25.69% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.11 | +800.90% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $104.43 | -53.08% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $839.90 | -57.61% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $4.13 | +45.28% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $20.35 | +656.76% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $10.80 | +38.95% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $24.72 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $13.64 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $3.23 | +364.40% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $49.23 | +23.92% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $0.96 | +10,585.76% | 3 | Jan 17, 2018 |
AbbVie
Apr 17, 2025
Reiterates: Buy
Price Target: $214
Current: $173.00
Upside: +23.70%
Merck & Co.
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $77.98
Upside: +47.47%
Travere Therapeutics
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $14.92
Upside: +215.01%
ANI Pharmaceuticals
Apr 11, 2025
Reiterates: Buy
Price Target: $86
Current: $69.30
Upside: +24.10%
Johnson & Johnson
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $157.44
Upside: -
Assembly Biosciences
Mar 25, 2025
Initiates: Buy
Price Target: $31
Current: $9.70
Upside: +219.59%
Absci
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $3.10
Upside: +222.58%
Pfizer
Mar 18, 2025
Reiterates: Buy
Price Target: n/a
Current: $22.15
Upside: -
Vera Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $21.19
Upside: +187.87%
Insmed
Feb 25, 2025
Reiterates: Buy
Price Target: $101
Current: $72.47
Upside: +39.37%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $14.06
Upside: -
Sep 10, 2024
Initiates: Buy
Price Target: $6
Current: $0.71
Upside: +744.95%
Jun 18, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.77
Upside: -
Sep 7, 2023
Maintains: Neutral
Price Target: $19 → $20
Current: $7.44
Upside: +169.00%
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $0.29
Upside: +8,978.21%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $0.90
Upside: +904.69%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.84
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $14.71
Upside: +29.16%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $100.10
Upside: -2.10%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $27.05
Upside: +25.69%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $1.11
Upside: +800.90%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $104.43
Upside: -53.08%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $839.90
Upside: -57.61%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $4.13
Upside: +45.28%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $20.35
Upside: +656.76%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $10.80
Upside: +38.95%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $24.72
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $13.64
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $3.23
Upside: +364.40%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $49.23
Upside: +23.92%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $0.96
Upside: +10,585.76%